Treace Medical Concepts, Inc. (NASDAQ: TMCI) reported Q2 EPS of ($0.34), $0.05 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $44.5 million versus the consensus estimate of $43 million.

GUIDANCE:

Treace Medical Concepts, Inc. sees FY2024 revenue of $201-211 million, versus the consensus of $205.5 million, representing growth of 7% to 13%, compared to full-year 2023.

The Company continues to expect Adjusted EBITDA to improve approximately 50% compared to full-year 2023.

For earnings history and earnings-related data on Treace Medical Concepts, Inc. (TMCI) click here.